Moreover, combination of Birinapant and Ralimetinib could be also useful for that number of patients with LKB1- and KRAS-mutated NSCLC, for whom, no targeted therapies are available yet, although the recent introduction of KRAS G12C specific inhibitors could make KRAS druggable (33). Here, STK11 is linked to non-small cell lung carcinoma.